Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy. The phase 3 trial, which enrolled more than 29,000 participants across the U.S. and Mexico, also demonstrated the vaccine to be safe. Additionally, the Novavax vaccine maintained a 93% efficacy against COVID-19 variants that emerged between January and April of this year.

The vaccine uses recombinant nanoparticle technology to generate a coronavirus spike protein-generated antigen. The company says the vaccine is stored and stable at 2-8 degrees Celsius (about 35-46 degrees Fahrenheit), enabling the use of existing vaccine supply chain channels for distribution.

Related News Articles

Headline
The AHA yesterday joined the U.S. Chamber of Commerce and American Medical Association in urging the 11th Circuit Court of Appeals to void a district court…
Headline
All clinicians should get vaccinated against COVID-19, encourage their staff and patients to get vaccinated, and recommend immunocompromised patients continue…
Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…